Compare ZLAB & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZLAB | TARS |
|---|---|---|
| Founded | 2013 | 2016 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.7B |
| IPO Year | 2017 | 2020 |
| Metric | ZLAB | TARS |
|---|---|---|
| Price | $18.35 | $60.39 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 6 |
| Target Price | $49.60 | ★ $89.00 |
| AVG Volume (30 Days) | ★ 598.6K | 504.6K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 38.46 | ★ 48.21 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $460,156,000.00 | $451,360,000.00 |
| Revenue This Year | $9.75 | $56.43 |
| Revenue Next Year | $26.03 | $30.19 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 15.33 | ★ 146.71 |
| 52 Week Low | $15.96 | $38.51 |
| 52 Week High | $44.34 | $85.25 |
| Indicator | ZLAB | TARS |
|---|---|---|
| Relative Strength Index (RSI) | 35.16 | 35.83 |
| Support Level | $16.88 | $48.20 |
| Resistance Level | $19.64 | $76.47 |
| Average True Range (ATR) | 0.95 | 3.40 |
| MACD | -0.51 | -0.02 |
| Stochastic Oscillator | 0.22 | 16.43 |
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.